Evidence map›Paper›PMID 38527949›Full record

Trial reportPharmacology research & perspectives2024

Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia.

Guangqing Xiao, Hironobu Tsukada, Yu-Luan Chen, Lei Shi, Seth C Hopkins, Gerald R Galluppi

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Pharmacology research & perspectives, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Guangqing XiaoSumitomo Pharma America, Inc, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0009-0004-5479-9126
Hironobu TsukadaSumitomo Pharma America, Inc, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0009-0009-8039-7194
Yu-Luan ChenSumitomo Pharma America, Inc, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0002-2866-3602
Lei ShiSumitomo Pharma America, Inc, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6065-1452
Seth C HopkinsSumitomo Pharma America, Inc, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0003-3999-2281
Gerald R GalluppiSumitomo Pharma America, Inc, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6705-3084
Sumitomo Dainippon Pharma (United States) · US

Funding

Otsuka Pharmaceutical Development & Commercialization, Inc.Sumitomo Pharma America, Inc.
6 · The paper itself

Abstract

Ulotaront (SEP-363856) is a TAAR1 agonist, with 5-HT1A agonist activity, currently in clinical development for the treatment of schizophrenia. In vitro studies indicate ulotaront is an OCT2-specific inhibitor with IC

Indexed as

MetforminPyransSchizophreniaAdultChromatography, LiquidCross-Over StudiesDrug InteractionsHumansOrganic Cation Transporter 2Single-Blind MethodTandem Mass SpectrometryMetforminOrganic Cation Transporter 2PyransSEP-363856drug interactionsdrug transportersschizophreniaTAAR1ulotaront

Identifiers

PMID38527949
PMCPMC10963303
OpenAlexW4393199103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.